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Abstract P2X7 receptor/channels mediate ATP-induced apo-
ptosis in a range of cells including lymphocytes. HEK293 cells
were transfected with wild-type human P2X7 receptor or site-
directed mutant constructs (K193A, K311A and E496A) known
to be non-functional from measurements of barium/ethidium in-
£ux in the presence of ATP or 2P,3P-O-(4-benzoylbenzoyl)-ATP.
An antibody was designed against an epitope from a loop ad-
jacent to the extracellular ATP site. The epitope was unavail-
able in cells expressing normal functional surface receptors.
Non-functional surface receptors as well as intracellular recep-
tors selectively bound the antibody. So did B-lymphocytes from
chronic lymphocytic leukemia patients expressing non-function-
al (E496A) mutant receptor.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Purinergic receptors of type P2X are fast, ligand-gated cat-
ion channels that open in response to the binding of extracel-
lular ATP. The seven subtypes designated P2X17 exhibit ex-
tensive homology (30^40%), particularly in structurally
important elements such as disul¢de bridges in the extracellu-
lar domain located between the two transmembrane domains
[1]. Each subtype has a short N-terminal sequence but the
long intracellular C-terminal domain is unique to P2X7 and
is thought to confer time-dependent dilation of the channel
into a pore that is able to transport large organic cations such
as ethidium and Yo-Pro (quinolinium, 4-[(3-methyl-2(3H)-
benzoxazolylidene) methyl]-1-[3-(trimethylammonio) propyl]-
diiodide) with molecular weights of up to 375 Da [2,3].
P2X7 receptors form trimeric or larger homomeric structures
[4] that are found in a range of cells including astrocytes [5],
endothelial cells [6], rat prostatic epithelial cells [7], monocytes
[8], lymphocytes [9] and macrophages [10]. A mutation at
position 496 in the carboxy-terminal tail leads to loss of the
permeability properties of P2X7 for both small and large in-
organic cations [11]. Similarly, site-directed mutagenesis of
either of the two lysines K193 and K311 fully inhibits the
normal function of P2X7 by a¡ecting the binding of agonist
through the phosphate side chain of ATP or ATP analogues
[3]. Moreover, residue 214 was found to be associated with an
ATP binding site based on marked species di¡erences in ago-
nist dissociation rates between rat, mouse and human P2X7
[12].
While the exact location of the ATP binding pocket in
P2X7 is uncertain, the segment around 193^214 was examined
for suitability as an epitope that may alter its exposure to an
antibody in the presence of bound agonist in order to discrim-
inate between surface receptors that are active and those that
are inactive in the absence of bound agonist. The successful
production of an antibody that binds only to non-functional
receptors as measured by their ability to form pores capable
of taking up barium/ethidium provides structural insight into
the mechanism of action of agonist and shows that cells ex-
pressing non-functional cytolytic P2X7 may be detected selec-
tively using this probe.
2. Materials and methods
2.1. Materials
ATP, BzATP, ethidium bromide, barium chloride, RPMI 1640 me-
dium, D-glucose, and bovine serum albumin were obtained from Sig-
ma (St. Louis, MO, USA); Ficoll-Hypaque (density 1.077), GFX1
PCR DNA and Gel Band Puri¢cation Kit from Amersham Pharma-
cia (Uppsala, Sweden); Cy3-conjugated anti-rabbit Ig antibody from
Jackson ImmunoResearch (West Grove, PA, USA); A⁄gel 10 from
Bio-Rad (Hercules, CA, USA); HEPES, LipoFectamine1 2000 re-
agent, Taq DNA polymerase, Opti-MEM I medium from Life Tech-
nologies (Gaithersburg, MD, USA); The Wizard Genomic DNA Pu-
ri¢cation Kit from Promega (Madison, WI, USA); QIAquick Gel
Extraction Kit from Qiagen (Australia); QuikChange1 Site-Directed
Mutagenesis Kit from Stratagene (La Jolla, CA, USA).
2.2. Antibody production
Using identical methods as described earlier [5], an antibody was
raised in rabbit to the epitope G200^C216 in human P2X7. The pres-
ence of a proline at 210 confers a cis/trans isomerization on the pep-
tide. Only the cis conformer produced an antibody that recognized the
non-functional receptors since site-directed mutagenesis of Pro210 to
lock the peptide in a trans con¢guration produced a P210A P2X7
receptor that was fully functional [3] and that was unable to bind
the antibody. Speci¢city of the antibody was checked in the usual
ways [5] with adsorption with conjugate peptide and free peptide
eliminating binding. A⁄nity puri¢cation of the protein G-puri¢ed
IgG fraction was carried out using the epitope bound to A⁄gel-10
(Bio-Rad). Western blots of HEK cells transfected with mutant
E496A or K193A P2X7 receptor show a single band corresponding
to the full-length protein at 80 kDa.
2.3. Tissue culture
HEK293 cells were transfected with cDNAs encoding human wild-
type or a mutant construct of P2X7 receptors using LipoFectamine
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2000. Cells were maintained in RPMI 1640 complete medium supple-
mented with 10% heat-inactivated fetal calf serum, 2 mM glutamine,
and 0.02 mg/ml gentamicin at 37‡C, 5% CO2. Truncated, germline
and mutant pCI-P2X7 plasmids were transfected into HEK293 cells
as described [11].
2.4. Site-directed mutagenesis
The full-length clone of hP2X7 (GenBank accession number
Y09561) was prepared as described [11]. The QuikChange1 Site-Di-
rected Mutagenesis Kit (Stratagene) was used according to the man-
ufacturer’s instructions to perform point mutations in the hP2X7 re-
ceptors at K193, P210, K311 and E496 as described [3]. Site-directed
mutations were con¢rmed by sequence analysis.
2.5. Immuno£uorescent staining
Immuno£uorescent staining and confocal microscopy of HEK293
cells and human B-lymphocytes incubated on collagen-coated glass
coverslips were performed as described [13,14] using a P2X7 polyclon-
al antibody [14] and the new antibody to non-functional receptors.
Cells were visualized with a Leica TCS NT UV laser confocal micro-
scope system as previously described [13].
2.6. Ethidium in£ux measurement by £ow cytometry
Flow cytometry was used to quantitate ethidium bromide uptake as
described [15]. Brie£y, cells (106) were labeled with the appropriate
antibody and were then washed once and resuspended in 1 ml of
bu¡er containing 10 mM HEPES, 150 mM KCl, 5 mM D-glucose,
0.1% bovine serum albumin, pH 7.5 and 37‡C. Cells were analyzed at
1000 events/s on a FACSCalibur £ow cytometer (Becton Dickinson,
San Jose, CA, USA). They were gated by forward and side scatter. All
samples were stirred. Ethidium (25 WM) was added followed after 40 s
by 1 mM ATP. Linear mean channel of £uorescence intensity for each
gated subpopulation over successive intervals of 5 s was analyzed
using WinMDI software (Joseph Trotter, V 2.7) and plotted against
time.
2.7. Barium in£ux using Fura-red
HEK293 cells and B-lymphocytes (4U106) were incubated with
Fura-red (1 Wg/ml) for 30 min at 37‡C in HEPES-bu¡ered NaCl
medium as described previously [11].
2.8. Patient samples
Heparinized venous blood from chronic lymphocytic leukemia
(CLL) patients and normal volunteers was diluted with an equal vol-
ume of RPMI 1640 medium and the mononuclear cells separated by
density gradient centrifugation as described [14].
3. Results
3.1. Functional analysis of pore formation of P2X7 on B-cells
by ATP-induced uptake of ethidium
Uptake of the £uorescent dye ethidiumþ measured by £ow
cytometry was used as an indicator of the £ux of a larger
permeant through the P2X7 pore. ATP did not stimulate
ethidium uptake in B-cells expressing homozygous mutant
P2X7 E496A from samples derived from blood taken from
either normal subjects or CLL patients. In contrast, ATP
produced a substantial increase in the rate of ethidium in£ux
in B-cells taken from normal subjects and CLL patients ex-
pressing wild-type P2X7 (Fig. 1). Identical results were ob-
tained (data not shown) using £uorometry in which the entry
of Ba2þ via the P2X7 channel in cells loaded with Fura-2 was
examined in both HEPES-bu¡ered KCl bu¡er and sucrose
bu¡er [16]. The 496 mutant receptors in normal and CLL
patients were unable to take up Ba2þ. Identical results have
been shown using HEK293 cells transfected with K193A and
K311A mutant P2X7 while the P201A mutant was found to
be functional [3].
3.2. Expression of P2X7 constructs in transiently transfected
HEK293 cells
Confocal microscopy showed wild-type P2X7 (Fig. 2a) and
mutants E496A (Fig. 2c), K193A (Fig. 2e), K311A (Fig. 2g)
and P210A (Fig. 2i) expressed equally strongly on the surface
of HEK293 cells where they were labeled using Cy3 bound to
a polyclonal P2X7 antibody conjugated via anti-rabbit IgG.
Negative controls included non-transfected cells and wild-type
cells labeled in the presence of 10 WM adsorption control pep-
tide epitope. Under these conditions all binding was abol-
ished. The right-hand panels show cells labeled with the anti-
body to non-functional P2X7. No binding occurs on the
surface of wild-type cells (Fig. 2b). This negative staining is
identical to the results obtained with non-transfected HEK
cells either permeabilized or non-permeabilized labeled with
either antibody and is also the same as the result found in
staining the functional P210A receptors (Fig. 2j). The three
non-functional receptors E496A (Fig. 2d), K193A (Fig. 2f)
and K311A (Fig. 2h) reveal clear binding on the cell surfaces.
Confocal microscopy of ¢xed and permeabilized HEK cells
expressing wild-type P2X7 showed that the general purpose
polyclonal P2X7 antibody (Fig. 2k) bound as well as the anti-
body to non-functional receptor (Fig. 2l) indicating that both
epitopes are available on intracellular P2X7 protein.
3.3. Surface expression of P2X7 in B-lymphocytes
Confocal microscopy was employed to demonstrate that
wild-type B-cells expressed P2X7. The receptors were labeled
on the cell surface using anti-rabbit Cy3-bound IgG second-
ary to a polyclonal P2X7 antibody (Fig. 3a). Identical results
were obtained in labeling wild-type CLL B-cells (Fig. 3c),
B-cells from normal subjects who were homozygous for the
E496A mutation (Fig. 3e) and B-cells from CLL patients who
also were homozygous for the E496A mutation (Fig. 3g). The
right-hand panels show cells labeled with the antibody to non-
functional P2X7. Both wild-type normal (Fig. 3b) and wild-
type CLL (Fig. 3d) expressed P2X7 receptors but the antibody
selective for non-functional receptors was unable to bind to
them. In contrast, the antibody selective for non-functional
receptors was able to bind to normal (Fig. 3f) and CLL
Fig. 1. ATP-induced ethidium uptake into B-cell lymphocytes. Mean
channel £uorescence intensity (ordinate) measured over 5 s intervals
for normal wild-type P2X7 (closed circles), normal CLL P2X7 (open
circles), normal, E496A homozygous P2X7 (¢lled triangles) and
CLL E496A homozygous P2X7 (open triangles).
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(Fig. 3g) B-cells homozygous for the E496A mutation that
have no pore function. The binding of each antibody to these
non-functional receptors was equally strong.
6
Fig. 2. Confocal microscope images of human and mutant P2X7 re-
ceptor expression on HEK293 cells. Non-permeabilized HEK293
cells transiently transfected with either (a,b) wild-type, (c,d) E496A,
(e,f) K193A, (g,h) K311A, (i,j) P210A using either an antibody di-
rected against a conformationally insensitive epitope on P2X7 (left-
hand panels) or an antibody designed to detect non-functional re-
ceptor (right-hand panels). All cells were labeled with one of the
rabbit primaries and subsequently with Cy3-conjugated anti-rabbit
IgG antibody. Field widths are 25 Wm. Permeabilized HEK293 cells
transfected with wild-type P2X7 were similarly labeled (k,l) showing
the non-functional receptor antibody detects intracellular protein.
Field widths are 10 Wm.
Fig. 3. Confocal microscope images of human and mutant P2X7 re-
ceptor expression on the surface of B-cell lymphocytes. B-cell lym-
phocytes from normals expressing either (a,b) fully functional wild-
type P2X7 or (e,f) non-functional E496A mutant P2X7, and B-cell
lymphocytes from B-CLL patients expressing either (c,d) fully func-
tional wild-type P2X7 or (g,h) non-functional E496A mutant P2X7
using either an antibody directed against a non-conformationally
sensitive epitope on P2X7 (left-hand panels) or an antibody designed
to detect non-functional receptor (right-hand panels). All cells were
labeled with the rabbit primary and subsequently with Cy3-conju-
gated anti-rabbit IgG antibody. Field widths are 10 Wm.
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4. Discussion
Surface expression of P2X7 receptors on lymphocytes may
be maintained at normal levels while still exhibiting a loss of
function [11]. In normal leukocytes a close correlation is ob-
served between ATP-induced ethidium uptake and surface
expression of P2X7 receptors [17]. The inability of the recep-
tor/channels to form cytolytic pores may result from reduced
availability of ATP [3] and/or a loss of control in the P2X7-
associated anchorage proteins [11]. The removal of a positive
charge at the extracellular ATP binding site caused by sub-
stitution of alanine for lysine at either 193 or 311 or the
removal of a negative charge at an intracellular location
caused by the mutation of a glutamic acid (496) into an ala-
nine appears equally e⁄cient at abolishing the ATP-induced
uptake of both small and large cation permeants, the former
through direct e¡ects on charge conservation at the ATP site
and the latter due to presumed disruption to channel packing.
The K193A and K311A mutant receptors are clearly non-
functional, being entirely unable to form cytolytic pores while
the E496A mutant receptors can re-establish some pore for-
mation at very high expression levels in HEK cells, although
not when expressed as homozygous mutant P2X7 receptors in
B-lymphocytes (unpublished results). The antibody speci¢cally
designed to bind to non-functional receptors readily com-
plexes with intracellular (non-functional P2X7) receptors in-
dicating that the epitope is available on monomers or intra-
cellular aggregates in the absence of bound ATP as well as on
the above mutant receptors tra⁄cked to and inserted in the
plasma membrane. Thus there are no impediments to anti-
body binding by possible glycosylation sites on the epitope.
Rather, the epitope is normally conformationally unavailable
in wild-type functional expressed receptor.
Of the 20 amino acids, proline is the most likely to adopt
the cis isomeric form because of its unique side chain that is
linked to the main chain nitrogen thereby acting to reduce the
energy di¡erence between the cis form and the more stable
trans form. Cis-proline has about 25% of the stability of trans-
proline, very much higher than any of the other amino acids.
Cis^trans isomerization is the rate-limiting step in the folding
of some proteins. Many proteins such as Pin1/Cdc25 [18] and
ribonuclease A at Pro 93 [19] utilize cis^trans-proline isomer-
ization to regulate protein function. In the chosen P2X7 epi-
tope segment adjacent to the ATP binding site from 200 to
216, only one proline is present (Pro210). As discussed, this
segment is exposed only in the absence of bound ATP being
completely hidden in functional receptors expressed on the
plasma membrane. Pro210 is conserved in mouse, rat and
human P2X7 sequences. Locking Pro210 in trans by exchang-
ing proline for alanine by site-directed mutagenesis produces a
functional receptor [3]. Moreover, the antibody designed spe-
ci¢cally for non-functional receptors is unable to bind to this
P210A mutant due to the non-exposure of the epitope in trans
con¢guration. This indicates that there are no components to
a trans conformer remaining in the puri¢ed serum. It therefore
appears likely that Pro210 adopts a trans con¢guration in
functional receptors where ATP is bound but a cis con¢gura-
tion in non-functional receptors where ATP is unbound. Fur-
thermore, replacement of Ile214, adjacent to Pro210 in the
selected epitope, a¡ects dissociation of agonist binding [12]
thereby a¡ecting the potency of ATP, further indicating that
Ile214, at the end of the epitope sequence, is associated with
an ATP binding site.
Switching between functional and non-functional receptor
conformations through cis/trans conformational change in
Pro210 seems to apply irrespective of whether the lack of
observed pore function is caused by lack of bound ATP or
by disruption to P2X7 monomer packing within the channel/
pore. Thus inhibition of intracellular anchorage protein pack-
ing in homozygous E496A P2X7 receptors in lymphocytes
appears to interfere with the ability of ATP to bind to the
extracellular domain. It may be that the monomers are unable
to form appropriate intermonomer ATP sites leaving the epi-
tope 200^216 exposed and thus able to bind the antibody to
non-functional receptors. Other conformationally sensitive
antibodies have been described, usually developed by appro-
priate selection of monoclonals [20,21], but we have shown
that careful selection of structural epitopes can achieve the
same result with a polyclonal antibody.
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